Familial isolated primary pigmented nodular adrenocortical disease associated with a novel low penetrance PRKAR1A gene splice site mutation
- PMID: 20190548
- DOI: 10.1159/000277629
Familial isolated primary pigmented nodular adrenocortical disease associated with a novel low penetrance PRKAR1A gene splice site mutation
Abstract
Background/aims: Primary pigmented nodular adrenocortical disease (PPNAD) is associated with inactivating germline protein kinase A regulatory subunit type 1-alpha (PRKAR1A) mutations and loss of heterozygosity at the 17q22-24 locus in approximately 50% patients. PRKAR1A mutations are observed in both isolated PPNAD (iPPNAD) and Carney complex (CNC). Most mutations result in a functionally null-allele and exhibit high penetrance. We genotyped members of an extended family for a novel PRKAR1A mutation and undertook detailed phenotyping for CNC in the affected individuals.
Methods: A 10.5-year-old male was diagnosed with PPNAD; the patient's mother also had iPPNAD. A 13-year-old sibling and 7 other relatives (mean age 58.2, range 29.1-80.2 years) were referred for PRKAR1A mutation analysis.
Results: DNA analysis of the index case and parent revealed a novel germline heterozygous PRKAR1A mutation at the +1 position of the acceptor site of intron 3 [c.349 G>T]. The same heterozygous splice site mutation was present in the sibling with no PPNAD or CNC manifestations and 2 other individuals aged 54.9 and 57.1 years who had subclinical Cushing's syndrome but no features of CNC.
Conclusion: We conclude that c.349 G>T, a novel splice site germline PRKAR1A defect, has low penetrance resulting in incomplete clinical expression in this kindred.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.Front Endocrinol (Lausanne). 2024 Jun 26;15:1356870. doi: 10.3389/fendo.2024.1356870. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39006359 Free PMC article.
-
PRKAR1A mutations in primary pigmented nodular adrenocortical disease.Pituitary. 2006;9(3):211-9. doi: 10.1007/s11102-006-0266-1. Pituitary. 2006. PMID: 17036196 Review.
-
A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds.J Clin Endocrinol Metab. 2006 May;91(5):1943-9. doi: 10.1210/jc.2005-2708. Epub 2006 Feb 7. J Clin Endocrinol Metab. 2006. PMID: 16464939
-
A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer.J Clin Endocrinol Metab. 2012 Feb;97(2):351-9. doi: 10.1210/jc.2011-2244. Epub 2011 Nov 23. J Clin Endocrinol Metab. 2012. PMID: 22112814 Free PMC article.
-
Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease.J Clin Endocrinol Metab. 2002 Sep;87(9):4324-9. doi: 10.1210/jc.2002-020592. J Clin Endocrinol Metab. 2002. PMID: 12213893
Cited by
-
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.Front Endocrinol (Lausanne). 2024 Jun 26;15:1356870. doi: 10.3389/fendo.2024.1356870. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39006359 Free PMC article.
-
A novel splice site mutation of the PRKAR1A gene, C.440+5 G>C, in a Chinese family with Carney complex.J Endocrinol Invest. 2018 Aug;41(8):909-917. doi: 10.1007/s40618-017-0817-5. Epub 2018 Jan 9. J Endocrinol Invest. 2018. PMID: 29318463 Clinical Trial.
-
Novel genetic mutation in the background of Carney complex.Pathol Oncol Res. 2012 Apr;18(2):149-52. doi: 10.1007/s12253-012-9502-3. Pathol Oncol Res. 2012. PMID: 22297707 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources